Durata Therapeutics is moving its base from New Jersey to Chicago, "a fertile recruiting ground for us," CEO Paul Edick said. The company is preparing the send dalbavancin for review by the FDA as a weekly IV antibiotic.
Published in Brief:
|Compliance and Ethics Director||
Sysmex America, Inc.
|Director, Site Quality Management||
|Palm Springs, CA|
|Compliance Officer-Medical Products||
W. L. Gore